Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis

Main Article Content

Thomas Bieber
Department of Dermatology and Allergy, University Hospital, Bonn, Germany

Lisa Beck
2Department of Dermatology, Medicine and Pathology, University of Rochester Medical Center, Rochester, NY, USA

Andrew Pink
St. John's Institute of Dermatology, Guy’s and St. Thomas’ Hospitals, London, UK

Hidehisa Saeki
Department of Dermatology, Nippon Medical School, Tokyo, Japan

Lawrence Eichenfeld
UC San Diego

Thomas Werfel
Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany

Anders Rosholm
LEO Pharma A/S, Ballerup, Denmark

Mads Ropke
LEO Pharma A/S, Ballerup, Denmark

Amy Paller
Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago IL, USA

Keywords

IL-13, tralokinumab, atopic dermatits, skin microbiome

Abstract

N/A

References

1. Ogonowska P et al. Front. Microbiol. 2021; 11:567090;

2. Wollenberg A et al. Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19574. Online ahead of print;

3. Silverberg et al. Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.1957 3. Online ahead of print;

4. Guttman-Yassky E, etal. Poster presentation at AAD VMX 2021;

5. Guttman-Yassky E, et al. Late-breaking presentation at AAD VMX 2021.

Article Sidebar

Poster PDF
Published
Nov 5, 2021
DOI https://doi.org/10.25251/skin.5.supp.56

Article Details

How to Cite
Bieber, T. ., Beck, L., Pink, A., Saeki, H., Eichenfeld, L., Werfel, T., Rosholm, A., Ropke, M., & Paller, A. . (2021). Neutralizing interleukin-13 increases skin microbial diversity: results from a Phase 3, randomized, double-blind, placebo-controlled trial of tralokinumab in adult patients with atopic dermatitis. SKIN The Journal of Cutaneous Medicine, 5(6), s56. https://doi.org/10.25251/skin.5.supp.56
Issue
Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 > >>